The incretin/glucagon system as a target for pharmacotherapy of obesity

Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for many people. The pathophysiology of obesity is complex, and currently approved pharmacotherapies only target a few of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Prato, Stefano, Gallwitz, Baptist, Holst, Jens Juul, Meier, Juris J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Obesity Pharmacotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286339/
https://www.ncbi.nlm.nih.gov/pubmed/34713962
http://dx.doi.org/10.1111/obr.13372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286339/
https://www.ncbi.nlm.nih.gov/pubmed/34713962
http://dx.doi.org/10.1111/obr.13372

Ejemplares similares